Quidel Corporation
318 articles about Quidel Corporation
-
Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy
8/27/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today the following business update in advance of today’s presentation and investor meetings at the 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour.
-
Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour
8/27/2020
Aug. 27, 2020 18:32 UTC Quidel to Present Today at 13 th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour SAN DIEGO--( BUSINESS WIRE )-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour today, Thursday, August 27, 2020. Douglas Bryant,
-
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
8/20/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for Quidel’s Emergency Use Authorization (EUA) for the Sofia® SARS Antigen FIA has been amended to include either nasal or nasopharyngeal swabs.
-
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
8/20/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont,
-
National Study Finds Lyme Disease 10 Times Greater Than Reported to CDC; Quidel-Sponsored Webinar Reveals Prevalence and Patterns of Lyme Disease
8/19/2020
The number of Americans afflicted with Lyme disease was found to be 10 times greater than the 30,000 cases reported each year to the Centers for Disease Control and Prevention, according to a groundbreaking seven-year clinical study just released.
-
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
8/12/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Health Canada authorization to market and sell the Lyra® Direct SARS-CoV-2 Assay in Canada
-
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
8/10/2020
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland has allowed point-of-care testing for COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
-
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Mil Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
7/31/2020
Quidel Corporation announced that Quidel has entered into a preliminary letter contract with the National Institutes of Health through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative to support the expansion of its manufacturing capacity in San Diego for its diagnostic assays that test for SARS-CoV-2 Antigen using its Sofia® Fluorescence Immunoassay platform.
-
Quidel Reports Second Quarter 2020 Financial Results
7/30/2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2020.
-
Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
7/29/2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Canaccord Genuity 40th Annual Growth Conference, to be held virtually on Wednesday, August 13, 2020.
-
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
7/29/2020
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40 th Annual Growth Conference CORRECTION...Quidel Corporation SAN DIEGO--( BUSINESS WIRE )-- In the first paragraph, the date of the conference should read: Thursday, August 13, 2020 (instead of Wednesday, August 13, 2020). The corrected release reads: QUIDEL TO PRESENT VIRTUALLY AT THE CANACCORD GENUITY 40 th ANNUAL GROWTH CONFERENCE Quidel Corporation (NASDAQ:
-
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
7/13/2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second fiscal quarter 2020 financial results after market close on Thursday, July 30, 2020.
-
Quidel Announces Preliminary Revenue for Second Quarter 2020
7/6/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the second fiscal quarter of 2020 to be in the range of $201 million to $202 million, an increase of approximately 86% - 87% over the prior year quarter.
-
Quidel Corporation to Host Free Webinar Addressing the Prevention, Detection and Treatment of Lyme Disease
6/16/2020
An important webinar addressing the prevention, detection and treatment of Lyme disease—an affliction that impacts as many as 400,000 Americans each year—will be held on June 25, coinciding with the annual early stages of “Lyme season” in the United States.
-
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
6/11/2020
Quidel Corporation announced that Quidel has received funding from the Biomedical Advanced Research and Development Authority to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus.
-
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
6/11/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler has retired from the Company’s Board of Directors effective June 10, 2020. Mr. Schuler has served on the board since February 2006. “As a member of our Board for the last 14 years, Jack leaves a legacy of market leadership, a
-
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
6/9/2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing Quidel to run its Sofia® SARS Antigen FIA,
-
Knowing Signs and Symptoms of Lyme Disease Is Critical for Early Detection and Treatment, Says Industry-Leading Quidel
6/2/2020
With America on lockdown the past two months, many people turned to the woods for safe isolation and social distancing.
-
Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
5/26/2020
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it will present at the William Blair 40th Annual Growth Stock Conference to be held virtually on Wednesday, June 10, 2020.